Press releases

Growing pipeline of submitted bids and another period of solid results and operating cash flow for Mabion in Q1 2024

Very good results and successful implementation of Mabion Strategy in 2023

Nigel Stapleton to support Mabion’s sales growth in role of Business Development Director for Europe

Marty Henehan will strengthen Mabion’s sales operations as Vice President of Business Development for North America

Mabion presents ESG Strategy for 2024-2027

Following a very good period of Q1–Q3, Mabion raises expectations for the full year results in 2023

Changes in the composition of the Management Board of Mabion S.A.

Third consecutive quarter of very strong results,high profitability and consistent transformation towards CDMO

Mabion with agreement to buy new bioreactors, diversifies technology and opens to new customers

Mabion with a quarter of record results. Implementation of activities announced in the Strategy

Mabion announces Strategy for 2023-2027 and summarizes very good Q4 and full year 2022

Mabion expands collaboration with Novavax for vaccine antigen for COVID-19 variant Omicron

Mabion with tenth order under Novavax partnership

Mabion has received ODD status from the FDA for the drug MabionCD20 in the indication of autoimmune hemolytic anemia

Mabion has signed a loan agreement with the EBRD for $15 million (about PLN 66 million)

Mabion has secured approval from the FDA to designate MabionCD20 as an orphan drug for the indication of membranous nephropathy